Allos Therapeutics Inc. (ALTH) is in the Pharma Industry

• Sort by
• View Related Content by Tag

• Allos Therapeutics Inc. Q1 2008 Earnings Call Transcript

  Allos Therapeutics Inc. Q1 2008 Earnings Call Transcript

  Earnings calls 2008-05-26

  Tags: Allos Therapeutics Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Allos Therapeutics, Inc Q4 2007 Earnings Call Transcript

  Allos Therapeutics, Inc Q4 2007 Earnings Call Transcript

  Earnings calls 2008-04-17

  Tags: Allos Therapeutics Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

• Allos Therapeutics Q3 2007 Earnings Call Transcript

  Allos Therapeutics Q3 2007 Earnings Call Transcript

  Earnings calls 2007-11-05

  Tags: Allos Therapeutics Inc., Call Transcript, Earnings, Seeking Alpha, Financial Accounting, Finance

Additional Resources

• Allos Therapeutics Reports 2008 Second Quarter Results

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the second quarter of 2008. For the three months ended June 30, 2008, the Company reported a net loss of $11.8 million, or ($0.16) per share. This compares to a net loss of $10.4 million, or ($0.16) per...

  Articles 2008-08-05

• Allos Therapeutics to Present at the Collins Stewart Fourth Annual Growth Conference

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that members of the Company's senior management will present a corporate overview at the Collins Stewart Fourth Annual Growth Conference...

  Articles 2008-07-03

• Mergent, Inc. Announces Quarterly Rebalancing of HealthShares™ Indexes

  NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the quarterly rebalancing of the Indexes. The following securities will be added and deleted in the Indexes effective before...

  Articles 2008-06-17

• Allos Therapeutics to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that members of the Company's senior management will present a corporate overview at the Seventh Annual Needham & Company, LLC...

  Articles 2008-06-06

• Allos Therapeutics Announces Interim Data from Phase 1 Study of PDX in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

  Responses Observed in 50% of First 14 Evaluable Patients WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the presentation of interim data from its Phase 1 study of PDX pralatrexate with vitamin B12 and folic acid supplementation in patients with relapsed or refractory...

  Articles 2008-06-05

• Allos Therapeutics Announces Closing of Public Common Stock Offering

  Underwriters Exercise Overallotment Option to Purchase Additional 1,620,000 Shares WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today the closing of its previously announced underwritten public offering of 12,420,000 shares of newly issued common stock at a public offering price of $5.64 per share. The number of...

  Articles 2008-05-29

• Allos Therapeutics Announces Pricing of Public Offering of 10,800,000 Shares of Common Stock

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (Nasdaq:ALTH) announced the pricing of an underwritten public offering of 10,800,000 shares of newly issued common stock at a public offering price of $5.64 per share. The closing of the offering is expected to take place on May 29, 2008, subject to the satisfaction...

  Articles 2008-05-23

• Allos Therapeutics Announces Public Offering of 9,000,000 Shares of Common Stock

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (Nasdaq:ALTH) announced today that it is offering to sell, subject to market and other conditions, 9,000,000 shares of newly issued common stock in an underwritten public offering. In connection with the offering, the Company expects to grant the underwriters a 30-day option to purchase...

  Articles 2008-05-19

• Allos Therapeutics Reports Interim Response and Safety Data from Pivotal Phase 2 PROPEL Trial

  29% of First 65 Evaluable Patients Experienced Either a Complete or Partial Response WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (Nasdaq:ALTH) today reported interim response and safety data from the Company's pivotal Phase 2 PROPEL trial of PDX pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma PTCL....

  Articles 2008-05-15

• Allos Therapeutics Reports First Quarter 2008 Financial Results

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today reported results for the first quarter of 2008. For the three months ended March 31, 2008, the Company reported a net loss of $12.0 million, or $(0.18) per share. This compares to a net loss of $8.4 million, or $(0.14) per...

  Articles 2008-05-07

• Allos Therapeutics to Present at the Bank of America 2008 Healthcare Conference

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing small molecule therapeutics for the treatment of cancer, today announced that members of the Company's senior management will present a corporate overview at the Bank of America 2008 Healthcare Conference in Las Vegas. ...

  Articles 2008-05-06

• Allos Therapeutics to Report 2008 First Quarter Financial Results on May 7, 2008

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it will report 2008 first quarter financial results on Wednesday, May 7, 2008, before the U.S. financial markets open. Paul L. Berns, President and Chief Executive Officer, and other members of Allos' senior management will provide a...

  Articles 2008-04-24

• Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it has completed patient enrollment in PROPEL, the Company's pivotal Phase 2 trial of PDX pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma PTCL. "The completion of enrollment in our pivotal PROPEL trial, a quarter...

  Articles 2008-04-22

• Allos Therapeutics Reports 2007 Results

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (Nasdaq:ALTH) today reported results for its fiscal year ended December 31, 2007 and outlined its key objectives for 2008. For the year ended December 31, 2007, the Company reported a net loss of $39.4 million, or $0.60 per share, compared to a net loss...

  Articles 2008-02-27

• Allos Therapeutics to Report 2007 Results on February 27, 2008

  WESTMINSTER, Colo. -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that it will report 2007 financial results on Wednesday, February 27, 2008, before the open of the U.S. financial markets. Paul L. Berns, President and Chief Executive Officer, and other members of Allos' senior management will provide a...

  Articles 2008-02-11

• Review in Progress Allos Therapeutics, Inc.

  M2 PRESSWIRE-30 January 2008-The SI Report: Review in Progress Allos Therapeutics, Inc.C1994-2008 M2 COMMUNICATIONS LTD RDATE:30012008 Stocks were up for a third straight day Friday, following Microsoft's bright forecast and profit earnings that proved to be better than expected....

  Articles 2008-01-30

• Has added Allos Therapeutics Inc. to their watch list.

  M2 PRESSWIRE-28 January 2008-The Maybach Journal: Has added Allos Therapeutics Inc. to their watch listC1994-2008 M2 COMMUNICATIONS LTD RDATE:28012008 Maybach Financial is a syndicate of financial informants representing a true investing experience. Taking research from financial consultants, brokers, researchers,...

  Articles 2008-01-28